Alendronate Supply in 2026: A Provider's Perspective

Alendronate sodium remains the most widely prescribed oral bisphosphonate in the United States, with over 10 million prescriptions dispensed annually. As a first-line treatment for osteoporosis, any disruption in supply directly impacts patient outcomes and clinical workflows. This guide summarizes the current supply landscape and offers evidence-based strategies for managing patients during availability challenges.

Current Supply Status

As of March 2026, Alendronate is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages Resource Center. There is no official nationwide shortage designation.

However, clinicians and pharmacists across various regions have reported intermittent stock-outs at the retail pharmacy level. These localized supply disruptions are attributed to:

• Wholesaler allocation and distribution variability
• Regional demand surges exceeding local supply
• Individual manufacturer production scheduling
• Pharmacy inventory management practices

The multiple-manufacturer landscape for generic Alendronate (including Teva, Mylan/Viatris, Aurobindo, Sun Pharma, Cipla, and others) generally prevents prolonged nationwide shortages, but it does not eliminate localized or transient availability issues.

Clinical Impact of Supply Disruption

Adherence and Fracture Risk

Medication adherence is already a significant challenge in osteoporosis management. Studies have shown that only approximately 50% of patients remain adherent to oral bisphosphonates at one year. Supply disruptions compound this problem by:

• Creating involuntary gaps in therapy
• Eroding patient confidence in treatment reliability
• Increasing the likelihood of permanent discontinuation
• Potentially increasing fracture risk in non-adherent patients

Patient Communication

Proactive communication is essential. Patients who report difficulty finding Alendronate should receive clear guidance on alternative pharmacies, dosage form options, and — when appropriate — therapeutic alternatives.

Available Dosage Forms

When the standard 70 mg weekly tablet is unavailable, consider prescribing an alternative Alendronate formulation:

• Alendronate 10 mg daily tablets — Therapeutically equivalent to 70 mg weekly
• Alendronate 35 mg weekly tablets — For osteoporosis prevention
• Alendronate oral solution (70 mg/75 mL) — Weekly dosing; useful for patients with swallowing difficulty
• Binosto (alendronate 70 mg effervescent tablet) — Weekly dosing; dissolves in water before ingestion

These alternative forms may have different availability at the pharmacy level. Prescribing a less common form may actually improve the patient's chance of finding it in stock, as demand for these forms is lower.

Therapeutic Alternatives

When Alendronate is unavailable or a patient requires a change in therapy, the following alternatives are supported by clinical evidence:

Oral Bisphosphonates

• Risedronate (Actonel, Atelvia): Available as 5 mg daily, 35 mg weekly, or 150 mg monthly. Comparable efficacy for vertebral and non-vertebral fracture reduction. May have a modestly better upper GI tolerability profile.
• Ibandronate (Boniva): 150 mg monthly oral or 3 mg IV every 3 months. Proven efficacy for vertebral fracture reduction; evidence for non-vertebral fracture reduction is less robust than for Alendronate or Risedronate.

Parenteral Options

• Zoledronic acid (Reclast): 5 mg IV once annually. Excellent option for patients who cannot tolerate oral bisphosphonates or have esophageal pathology. Strong evidence for vertebral, non-vertebral, and hip fracture reduction.
• Denosumab (Prolia): 60 mg subcutaneous every 6 months. Non-bisphosphonate mechanism (RANKL inhibitor). Important consideration: discontinuation is associated with rapid bone loss and rebound vertebral fractures. Transition to a bisphosphonate is recommended before stopping Denosumab.

Anabolic Agents (Severe Osteoporosis)

• Teriparatide (Forteo): 20 mcg subcutaneous daily for up to 2 years
• Abaloparatide (Tymlos): 80 mcg subcutaneous daily for up to 2 years
• Romosozumab (Evenity): 210 mg subcutaneous monthly for 12 months (boxed warning for cardiovascular risk)

Anabolic agents are typically reserved for patients with severe osteoporosis, very high fracture risk, or treatment failure. They are not direct substitutes for routine Alendronate therapy.

Prescribing Strategies During Supply Disruption

1. Verify availability before prescribing. Recommend patients use MedFinder for Providers to help patients locate pharmacies with Alendronate in stock.
2. Consider alternative formulations. If the 70 mg tablet is scarce, the 10 mg daily tablet or oral solution may be available.
3. Prescribe with flexibility. Use "may substitute" or generic-only prescriptions to give pharmacists maximum flexibility in sourcing.
4. Facilitate early refills. Encourage patients to refill 7 days before supply runs out to provide a buffer against delays.
5. Document supply issues. Note in the chart when patients report inability to fill prescriptions, and document the clinical rationale for any therapeutic substitutions.
6. Monitor adherence closely. During supply disruptions, follow up with patients to ensure they have found the medication or an appropriate alternative.

Insurance and Formulary Considerations

Generic Alendronate is on the formulary of virtually all commercial and Medicare Part D plans, typically at Tier 1 (preferred generic) with copays ranging from $0-$15. Key considerations:

• Prior authorization: Rarely required for generic Alendronate
• Step therapy: Generic Alendronate is usually the first-step drug; switching to alternatives may require step therapy documentation
• Quantity limits: Standard limits are 4 tablets per 30 days (70 mg weekly) or 30 tablets per 30 days (10 mg daily)

If switching a patient to a non-bisphosphonate alternative (e.g., Denosumab), be prepared to submit prior authorization documentation, including evidence that bisphosphonate therapy was attempted or is contraindicated.

Patient Resources

Direct patients to these resources for assistance:

• MedFinder: medfinder.com — Pharmacy stock availability search
• GoodRx: Discount coupons that can reduce Alendronate to as low as $8-$10
• NeedyMeds: Patient assistance program directory
• Medicare Extra Help: For eligible patients on Medicare

For a patient-facing version of this information, see our articles on Alendronate shortage update for patients and how to find Alendronate in stock. For cost-saving strategies to share with patients, see our provider's guide to helping patients save on Alendronate.

Key Takeaways for Providers

• No official Alendronate shortage exists in 2026, but localized supply disruptions are occurring
• Multiple dosage forms and therapeutic alternatives are available
• Proactive communication with patients about supply issues improves adherence and outcomes
• Generic Alendronate remains affordable and widely covered by insurance
• Use MedFinder for Providers as a resource for both your practice and your patients